Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Xencor, Inc.
Xencor, Inc.
Hoffmann-La Roche
Daiichi Sankyo
Turning Point Therapeutics, Inc.
BioNTech SE
Hoffmann-La Roche
Servier
Catalysis SL
Deciphera Pharmaceuticals, LLC
Blueprint Medicines Corporation
Novartis
Merck Sharp & Dohme LLC
Sanofi